Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6

Rhea-AI Summary

Taysha Gene Therapies (Nasdaq: TSHA) will release first quarter 2026 financial results for the period ended March 31, 2026, and host a corporate update conference call and webcast on Wednesday, May 6, 2026 at 8:30 AM ET. Participants can access the live webcast via the company’s Events and Presentations page at ir.tayshagtx.com, and an archived replay will be available afterward.

News Market Reaction – TSHA

-0.48%

-0.48% Session close to close

In the Apr 29 session, TSHA declined 0.48%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement schedules the release of first quarter 2026 results and a conference call on May 6...

Analysis

This announcement schedules the release of first quarter 2026 results and a conference call on May 6, 2026 at 8:30 AM ET, continuing Taysha’s pattern of pre-announcing earnings events. The stock traded above its 200-day MA of $4.30 and within 6.8% of its 52-week high ahead of this notice. Investors may focus on how upcoming results update cash resources, clinical progress for TSHA-102, and any changes versus prior full-year 2025 disclosures.

Key Figures

Quarter end date: March 31, 2026 Earnings call date: May 6, 2026 Earnings call time: 8:30 AM Eastern Time

3 metrics

Quarter end date March 31, 2026 First quarter 2026 reporting period

Earnings call date May 6, 2026 Scheduled Q1 2026 results release and call

Earnings call time 8:30 AM Eastern Time Start time for Q1 2026 webcast and conference call

Previous Conferences,earnings date Reports

1 past event · Latest: Mar 12 (Neutral)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 12	Earnings date notice	Neutral	+2.1%	Announced timing and access details for full-year 2025 earnings call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Prior earnings-date scheduling news corresponded with a modest positive move, indicating neutral-to-slightly-positive reactions to such notices.

Recent Company History

Over the last several months, Taysha Gene Therapies has reported full-year 2025 results with a corporate update, scheduled earnings calls, announced inducement equity grants, and highlighted new preclinical data for TSHA-102. The prior earnings-date press release on Mar 12, 2026 saw a modest +2.1% move. Against this backdrop, the new first-quarter 2026 earnings date notice fits a pattern of frequent operational and clinical communication to the market.

Key Terms

adeno-associated virus, central nervous system

2 terms

adeno-associated virus medical

"advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic"

Adeno-associated virus (AAV) is a naturally occurring, small virus that researchers use as a safe carrier to deliver corrective genes into human cells, much like a specialized delivery van transporting instructions to a malfunctioning machine. It matters to investors because AAV-based therapies drive large development costs, unique manufacturing and regulatory risks, and the potential for high-value, one-time treatments that can significantly affect a biotech company’s future revenue and valuation.

central nervous system medical

"monogenic diseases of the central nervous system (CNS), today announced that it"

The central nervous system (CNS) is the body's main control center, made up of the brain and spinal cord, that processes information and directs movement, sensation and basic functions like breathing. For investors, CNS-related products and research matter because they face long development times, strict safety testing and regulatory hurdles; success or failure can dramatically affect a company’s costs, timelines and potential market value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DALLAS, April 29, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2026, and host a corporate update conference call and webcast on Wednesday, May 6, 2026, at 8:30 AM Eastern Time.

Participants may access the live webcast of the conference call from the Events and Presentations page of Taysha’s website at ir.tayshagtx.com. An archived replay of the webcast will be available on the Company’s website.

About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit www.tayshagtx.com.

Company Contact:
Hayleigh Collins
Senior Director, Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com

Media Contact:
Carolyn Hawley
Inizio Evoke
Carolyn.hawley@inizioevoke.com

FAQ

When will Taysha (TSHA) report Q1 2026 financial results and host the webcast?

Taysha will report Q1 2026 results and host a webcast on May 6, 2026 at 8:30 AM ET. According to the company, the release covers the quarter ended March 31, 2026 and will include a corporate update alongside financial results.

How can investors access the Taysha (TSHA) May 6, 2026 conference call and webcast?

Investors can access the live webcast on the company’s Events and Presentations page at ir.tayshagtx.com. According to the company, the webcast will be streamed live and an archived replay will be posted on the company website after the event.

What time is the Taysha (TSHA) May 6, 2026 corporate update conference call?

The corporate update conference call begins at 8:30 AM Eastern Time on May 6, 2026. According to the company, the call coincides with the Q1 2026 results release and will be available via live webcast for participants.

Will a replay of the Taysha (TSHA) May 6 webcast be available after the event?

Yes, an archived replay will be available on the company website after the live event. According to the company, the webcast replay will be posted on the Events and Presentations page for on-demand access following the May 6, 2026 call.

What period do the financial results Taysha (TSHA) will report on May 6 cover?

The financial results cover the quarter ended March 31, 2026. According to the company, the May 6 webcast will present results and a corporate update for the first quarter of 2026.